M28 Capital Management LP
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 14, 2025), M28 Capital Management LP reported 11 stock positions worth $73.0 million. Its top holding was Wave Life Sciences (WVE) at 62.7% of the portfolio, followed by TG Therapeutics (TGTX, 8.7%) and Invivyd (IVVD, 7.7%). Compared with Q4 2024, it reduced 1. The biggest sale was Springworks Therapeutics (SWTX, shares −50%).
- Most Recent 13F
- Q2 2026
- Location
- STAMFORD, CT
- CIK
- 0001807489
- Portfolio Value
- $73.0M (Q1 2025)
- SEC Filing
- 0000902664-25-002321 ↗ filed May 14, 2025
Holdings Value
Holdings 11 stocks · $73.0M
| WVE Wave Life Sciences Ltd. | 62.72% | 5,664,548 | $45.8M | No change |
| TGTX TG Therapeutics Inc. | 8.73% | 161,600 | $6.4M | No change |
| IVVD Invivyd Inc. | 7.67% | 9,248,250 | $5.6M | No change |
| BBIO Bridgebio Pharma Inc. | 5.74% | 121,200 | $4.2M | No change |
| RCKT Rocket Pharmaceuticals Inc. | 3.52% | 385,680 | $2.6M | No change |
| SWTX Springworks Therapeutics Inc. | 3.34% | 55,200 | $2.4M | Reduce -50.0% |
| GUTS Fractyl Health Inc. | 3.03% | 1,856,117 | $2.2M | No change |
| PRQR Proqr Therapeutics NV | 1.86% | 1,019,498 | $1.4M | No change |
| CRIS Curis Inc. | 1.50% | 521,059 | $1.1M | No change |
| ARWR Arrowhead Pharmaceuticals Inc. | 1.18% | 67,400 | $859K | No change |
| SLN Silence Therapeutics PLC-ADR | 0.72% | 185,100 | $522K | No change |
Portfolio Sells Q4 2024 → Q1 2025
| SWTX Springworks Therapeutics Inc. | Reduce -50.0% | 3.34% | −0.58 |
Portfolio Buys Q4 2024 → Q1 2025
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 9 | $47.2M | WVE, IVVD, TGTX, ARWR, GUTS |
| Q1 2026 | 9 | $53.8M | WVE, IVVD, TGTX, ARWR, PRQR |
| Q4 2025 | 9 | $137.6M | WVE, IVVD, TGTX, ARWR, GUTS |
| Q3 2025 | 9 | $68.0M | WVE, IVVD, TGTX, GUTS, ARWR |
| Q2 2025 | 9 | $58.6M | WVE, IVVD, TGTX, GUTS, PRQR |
| Q1 2025 | 11 | $73.0M | WVE, TGTX, IVVD, BBIO, RCKT |
| Q4 2024 | 11 | $101.9M | WVE, TGTX, RCKT, IVVD, SWTX |
| Q3 2024 | 11 | $91.0M | WVE, IVVD, RCKT, GUTS, TGTX |
| Q2 2024 | 11 | $77.1M | WVE, IVVD, RCKT, GUTS, SWTX |
| Q1 2024 | 11 | $135.3M | WVE, IVVD, GUTS, RCKT, SLN |